Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Nature Medicine (2)
Oncogene (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (3)

Subject Check one or more subjects to show results from those subjects only.

Diseases
Immunology
Microbiology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–3 of 3 results

Advanced filters: Author: Roderick McPhee Clear advanced filters

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

A third dose of the COVID-19 vaccine mRNA-1273 is safe and boosts SARS-CoV-2 neutralizing antibody titers almost two-fold higher than the peak levels observed after completion of a two-dose series, highlighting the potential clinical benefit of a booster dose.

Laurence Chu
Keith Vrbicky
Roderick McPhee
ResearchOpen Access03 Mar 2022
Nature Medicine

Volume: 28, P: 1042-1049
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

Preliminary and exploratory analyses show that a third dose of the COVID-19 vaccine mRNA-1273 or variant-modified boosters can boost levels of neutralizing antibodies against SARS-CoV-2 variants.

Angela Choi
Matthew Koch
Darin K. Edwards
ResearchOpen Access15 Sept 2021
Nature Medicine

Volume: 27, P: 2025-2031
Integration of proviral DNA into the PDGF β-receptor gene in HTLV-I-infected T-cells results in a novel tyrosine kinase product with transforming activity

Kenneth D Chi
Roderick A McPhee
Anton Scott Goustin
Research28 Aug 1997
Oncogene

Volume: 15, P: 1051-1057

Search

Search articles by subject, keyword or author

Show results from

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

Nature.com

nature.com sitemap

About Nature Portfolio

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
protocols.io
Nature Index

Publishing policies

Nature portfolio policies
Open access

Author & Researcher services

Reprints & permissions
Research data
Language editing
Scientific editing
Nature Masterclasses
Research Solutions

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Professional development

Nature Awards
Nature Careers
Nature Conferences

Regional websites

Nature Africa
Nature China
Nature India
Nature Japan
Nature Middle East

Privacy Policy
Use of cookies
Legal notice
Accessibility statement
Terms & Conditions
Your US state privacy rights

Search

Filter By:

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

Integration of proviral DNA into the PDGF β-receptor gene in HTLV-I-infected T-cells results in a novel tyrosine kinase product with transforming activity

Search

Quick links